Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

January 17, 2024

https://www.globenewswire.com/news-release/2024/01/17/2810599/25359/en/Groundbreaking-Randomized-Controlled-Trial-Reports-Excellent-Clinical-Outcomes-Using-CytoSorb-Intraoperatively-in-Heart-Transplant-Patients.html

PRINCETON, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports on excellent outcomes from a groundbreaking randomized controlled trial (RCT) using CytoSorb® blood purification during heart transplant, recently published in the European Society of Cardiology journal, ESC Heart Failure.

Read more at globenewswire.com

Related news for (CTSO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.